Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
H.R. 1458/S. 565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act: Met with Ways and Means committee staff; advocacy to increase co-sponsorship of the bill
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PKD FOUNDATION via PKD FOUNDATION
2010 · fourth_quarter · 4@
Report language to the FY 2011 Labor-Health and Human Services-Education Appropriations Act supporting PKD research at the National Institute of Diabetes, Digestive and Kidney Disease (NIDDK); support for increasing overall funding for the National Institutes of Health (NIH)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKD FOUNDATION via PKD FOUNDATION
2010 · fourth_quarter · Q4
Source: Senate LDA
H.R. 1458/S. 565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act: Met with Ways and Means committee staff; advocacy to increase co-sponsorship of the bill
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2009
Client: PKD FOUNDATION · Firm: PKD FOUNDATION
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
Report language to the FY 2011 Labor-Health and Human Services-Education Appropriations Act supporting PKD research at the National Institute of Diabetes, Digestive and Kidney Disease (NIDDK); support for increasing overall funding for the National Institutes of Health (NIH)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKD FOUNDATION via PKD FOUNDATION
2010 · third_quarter · Q3
Hosted Congressional Briefing on July 29, 2010 in conjunction with the Congressional Kidney Caucus to discuss PKD Foundation and our public-private partnership with the FDA (Critical Path Institute and C-Disc); Meetings with various HELP Committee and Energy and Commerce Committee staff to brief them on efforts
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKD FOUNDATION via PKD FOUNDATION
2010 · second_quarter · Q2
FY 2011 Defense Appropriations bill: Followed up on requests in the House for establishing a polycystic kidney disease (PKD) research program funded at $5 million in the DoD Congressionally Directed Medical Research Program; FY 2011 Defense Appropriations bill: Filed and followed up on requests in the Senate for keeping PKD listed as a disease eligible to compete for funding under the DoD Peer Reviewed Medical Research Program
H.R. 1458/S. 565 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act: Met with Ways and Means committee staff; advocacy to increase co-sponsorship of the bill
FY 2011 Labor-HHS-Education Appropriations bill: Followed up on requests for report language referencing polycystic kidney disease (PKD); Advocate for overall increase in funding for the National Institues of Health (NIH)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKD FOUNDATION via PKD FOUNDATION
2010 · first_quarter · Q1
PKD research in the Department of Defense Peer-Reviewed Medical Reserach Program and the Congressionally Directed Medical Research Programs
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
PKD FOUNDATION via PKD FOUNDATION
2009 · fourth_quarter · Q4
NIH report language request - FY 2010 Labor-HHS-Education Appropriations Act PKD listed in the Peer Reviewed Medical Reserach Program (PRMRP) in the FY 2010 Defense Appropriations Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PKD FOUNDATION via PKD FOUNDATION
2009 · fourth_quarter · RR
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)
NIH/NIDDK funding for PKD research and report language with in the FY 2010 Labor-Health and Human Services- Education Appropriations bill; PKD research within the Peer Reviewed Medical Reserach Program(PRMRP) and the Congressionally Directed Medical Research Programs (CDMRP) in the FY 2010 Defense Appropriations bill; Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR 1458/S 565)